Annual results show revenue and profit growing together.
Revenue rose from KRW 7.64 billion in 2022 to KRW 8.23 billion in 2023 (up 7.6% year on year), KRW 10.5 billion in 2024 (up 27.8%), and KRW 15.1 billion in 2025 (up 43.8%), marking three straight years of growth from 2023 through 2025, with 2025 the largest year in the 2022 to 2025 span.
Operating profit fell to a low of KRW 164 million in 2023 (down 84.5% year on year), then rose to KRW 1.5 billion in 2024 (up 815.3%) and KRW 3.72 billion in 2025 (up 147.8%), growing for two consecutive years from 2024 through 2025.
Operating margin moved from 13.8% in 2022 to 2.0% in 2023, then 14.3% in 2024 and 24.6% in 2025.
Profit attributable to controlling shareholders fell from KRW 1.25 billion in 2022 to KRW 463 million in 2023 (down 63.0%), then rose to KRW 2.44 billion in 2024 and KRW 4.47 billion in 2025, growing for two consecutive years.
Net profit including non-controlling interests was reported at the same amounts as profit attributable to controlling shareholders in every year from 2022 to 2025. The company has said that high manufacturing costs at the launch of new products ease once production moves to mass-production levels (Edaily report).
The debt ratio was 8.9% in 2022 and 7.6% in 2025. At year-end 2025, total equity was KRW 30.7 billion, all attributable to controlling shareholders, and total liabilities were KRW 2.33 billion. Operating cash flow was KRW 1.22 billion in 2022, KRW 381 million in 2023, KRW 1.44 billion in 2024 and KRW 3 billion in 2025.
The quarterly pattern was more volatile.
Revenue went from KRW 4.03 billion in Q3 2025 to KRW 4.55 billion in Q4 2025 (up 12.7% quarter on quarter), then KRW 3.82 billion in Q1 2026 (down 15.9%), KRW 5.35 billion in Q2 2026 (up 39.9%) and KRW 4.68 billion in Q3 2026 (down 12.6% quarter on quarter, up 15.9% year on year).
Operating profit peaked at KRW 1.64 billion in Q2 2026 (up 115.4% quarter on quarter) before falling to KRW 1.14 billion in Q3 2026 (down 30.5% quarter on quarter, down 3.3% year on year).
Profit attributable to controlling shareholders dropped to KRW 441 million in Q3 2026 (down 71.5% quarter on quarter, down 65.7% year on year), a sharp gap from the KRW 1.14 billion operating profit in the same quarter.
Profit attributable to controlling shareholders for the latest four quarters, Q4 2025 through Q3 2026, totals KRW 4.65 billion.
In its November 11, 2026 disclosure, the company said cumulative revenue and operating profit through Q3 were record highs, driven by domestic sales of its allergy products, where Allergy-Q line sales rose more than 50% year on year.